We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug & Device Products
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Publications
    • Webinar Training Pass
    • eCFR and Guidances
    • Books
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Topics » COVID-19

COVID-19
COVID-19 RSS Feed RSS

RedHill Touts Potential of Its Investigational Cancer Drug Against Omicron Subvariants

April 13, 2022
The company is working with regulators in the U.S., Europe and the UK to find ways to gain approval for this drug for the treatment of COVID-19. Read More

Moderna Recalls Nearly 800,000 Doses of Its COVID-19 Vaccine

April 12, 2022
The recall was issued following a report of a foreign body found in one vial at a vaccination center in Spain. Read More

FDA Updates EUA for J&J COVID-19 Vaccine to Extend Shelf Life

April 12, 2022
As of December 2021, only 17 million doses of the adenovirus-based J&J vaccine were administered in the U.S. Read More

Acuitas Therapeutics Sues Arbutus Biopharma Over mRNA-Delivery Patents

March 22, 2022
In its complaint, Acuitas argues that Arbutus and Genevant had nothing to do with the vaccine’s success and only sued after the Pfizer/BioNTech COVID-19 vaccine achieved “worldwide commercial success.” Read More

Two Companies Hit With FDA Warning Letters for Selling Unapproved and Misbranded Drugs for COVID-19

February 24, 2022
The FDA has accused two overseas companies of selling unapproved and misbranded drugs for COVID-19 to U.S. customers over the internet. Read More

Sanofi, GSK Seek Vaccine Authorization as Both Primary Series and Booster

February 24, 2022
Sanofi and GlaxoSmithKline (GSK) will very soon be taking their COVID-19 vaccine candidate to U.S. and European regulators as both a primary series and booster, touting its 58 percent efficacy against symptomatic disease as proof that the shot works in a world with multiple COVID-19 variants. Read More

Pfizer, BioNTech Delay Seeking COVID-19 Vaccine Authorization in Children Under Five

February 14, 2022
Pfizer and BioNTech announced Friday that they will hold off pursuing an expanded FDA Emergency Use Authorization (EUA) permitting use of their COVID-19 vaccine in children under age five, in order to gather more data on whether a third booster dose is needed. Read More

PhRMA Blasts WHO Efforts to Pause Patent Rights for COVID-19 Medicines

February 7, 2022
In a 269-page submission to U.S. Trade Representative, Katherine Tai, the Pharmaceutical Research and Manufacturers of America (PhRMA) spelled out the group’s objections to efforts by the World Health Organization (WHO) and other organizations to expand COVID-19 vaccines and treatments at the expense of intellectual property rights. Read More

COVID-19 Boosters Slash Risk of Omicron-Related Death in Older People

January 28, 2022
Protection against Omicron-related death in people 50 and older reached as high as 95 percent after a booster dose of a messenger RNA (mRNA) vaccine, the UK Health Security Agency (UKHSA) announced Thursday. Read More

Pfizer, Moderna COVID-19 Booster Dose Effective Against Omicron, CDC Says

January 24, 2022
A Moderna or Pfizer/BioNTech COVID-19 booster dose was found to give highly effective protection against the Delta and Omicron variants, the Centers of Disease Control and Prevention (CDC) said Friday. Read More

GSK and Vir Seek FDA Nod for Intramuscular Version of COVID-19 Antibody

January 18, 2022
GlaxoSmithKline (GSK) and Vir Biotechnology have developed an intramuscular version of their investigational monoclonal antibody infusion, sotrovimab, for the early treatment of COVID-19 and are asking the FDA to expand the drug’s Emergency Use Authorization (EUA) to include it. Read More

CBER Director Peter Marks Says Omicron-Specific Shots Might Not be Needed

January 18, 2022
As the Omicron variant rages, Peter Marks, the FDA’s top vaccine regulator, said that getting a booster dose earlier than six months after initial doses may be the best way to guard against the ubiquitous variant. Read More
Previous 1 2 3 4 5 6 7 8 9 … 164 165 Next

Upcoming Events

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 15Jun

    Recall Readiness: Dust Off Your SOPs, There’s a New Guidance in Town

  • 21Jun

    Medical Device Reporting: Best Practices and Common Pitfalls

  • 22Jun

    Meet CDRH’s New Strategic Priorities: Where the Center is Headed and How Devicemakers Can Keep Up

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

Featured Products

  • Biological Risk Evaluation and Management for Medical Devices

  • GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

  • MedMira Gets CE Mark for Its Multiplo Syphilis Antibody Test

  • FDA Lifts Clinical Hold on Ocugen COVID-19 Vaccine Clinical Trial

  • FDA Refuses Second Clearance to NeuroOne’s Evo sEEG Electrode

  • FDA Greenlights Dermavant’s Vtama Cream for Psoriasis

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Fax 703.538.7676 – Toll free 888.838.5578

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing